Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

M. H. Davidson,P. Toth,S. Weiss,J. Mckenney,D. Hunninghake,J. Isaacsohn,J. Donovan,S. Burke
DOI: https://doi.org/10.1002/CLC.4960240610
2001-06-01
Clinical Cardiology
Abstract:Background: Colesevelam hydrochloride is a novel, lipid‐lowering agent that binds bile acids with high affinity. A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐design study was conducted to assess the efficacy and tolerability of combination low‐dose colesevelam and lovastatin treatment in patients with primary hypercholesterolemia.
What problem does this paper attempt to address?